Secondary myopathy due to systemic diseases
Identifieur interne : 002181 ( Istex/Curation ); précédent : 002180; suivant : 002182Secondary myopathy due to systemic diseases
Auteurs : J. Finsterer [Autriche, Allemagne] ; W. N. Löscher [Autriche] ; J. Wanschitz [Autriche] ; S. Quasthoff [Autriche] ; W. Grisold [Autriche]Source :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 2016-12.
Abstract
Background: Some systemic diseases also affect the skeletal muscle to various degrees and with different manifestations. This review aimed at summarizing and discussing recent advances concerning the management of muscle disease in systemic diseases. Method: Literature review by search of MEDLINE, and Current Contents with appropriate search terms. Results: Secondary muscle disease occurs in infectious disease, endocrine disorders, metabolic disorders, immunological disease, vascular diseases, hematological disorders, and malignancies. Muscle manifestations in these categories include pathogen‐caused myositis, muscle infarction, rhabdomyolysis, myasthenia, immune‐mediated myositis, necrotising myopathy, or vasculitis‐associated myopathy. Muscle affection may concern only a single muscle, a group of muscles, or the entire musculature. Severity of muscle affection may be transient or permanent, may be a minor part of or may dominate the clinical picture, or may be mild or severe, requiring invasive measures including artificial ventilation if the respiratory muscles are additionally involved. Diagnostic work‐up is similar to that of primary myopathies by application of non‐invasive and invasive techniques. Treatment of muscle involvement in systemic diseases is based on elimination of the underlying cause and supportive measures. The prognosis is usually fair if the causative disorder is effectively treatable but can be fatal in single cases if the entire musculature including the respiratory muscles is involved, in case of infection, or in case of severe rhabdomyolysis. Conclusion: Secondary muscle manifestations of systemic diseases must be addressed and appropriately managed. Prognosis of secondary muscle disease in systemic diseases is usually fair if the underlying condition is accessible to treatment.
Url:
DOI: 10.1111/ane.12576
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002181
Links to Exploration step
ISTEX:630F32990B32178802FA502E5613B79C73861A80Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Secondary myopathy due to systemic diseases</title><author><name sortKey="Finsterer, J" sort="Finsterer, J" uniqKey="Finsterer J" first="J." last="Finsterer">J. Finsterer</name><affiliation wicri:level="1"><mods:affiliation>Krankenanstalt Rudolfstiftung, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Krankenanstalt Rudolfstiftung, Vienna</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: fifigs1@yahoo.de</mods:affiliation><country wicri:rule="url">Allemagne</country></affiliation><affiliation><mods:affiliation>J. Finsterer, Krankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna, AustriaTel.: +43 1 71165 92085Fax: +43 1 4781711e‐mail:</mods:affiliation><wicri:noCountry code="subField">4781711e‐mail:</wicri:noCountry></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: fifigs1@yahoo.de</mods:affiliation><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Loscher, W N" sort="Loscher, W N" uniqKey="Loscher W" first="W. N." last="Löscher">W. N. Löscher</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Wanschitz, J" sort="Wanschitz, J" uniqKey="Wanschitz J" first="J." last="Wanschitz">J. Wanschitz</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Quasthoff, S" sort="Quasthoff, S" uniqKey="Quasthoff S" first="S." last="Quasthoff">S. Quasthoff</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Graz Medical University, Graz, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Graz Medical University, Graz</wicri:regionArea></affiliation></author><author><name sortKey="Grisold, W" sort="Grisold, W" uniqKey="Grisold W" first="W." last="Grisold">W. Grisold</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Kaiser‐Franz‐Josef Spital, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Kaiser‐Franz‐Josef Spital, Vienna</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:630F32990B32178802FA502E5613B79C73861A80</idno><date when="2016" year="2016">2016</date><idno type="doi">10.1111/ane.12576</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-1BJ1TRPC-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002181</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002181</idno><idno type="wicri:Area/Istex/Curation">002181</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Secondary myopathy due to systemic diseases</title><author><name sortKey="Finsterer, J" sort="Finsterer, J" uniqKey="Finsterer J" first="J." last="Finsterer">J. Finsterer</name><affiliation wicri:level="1"><mods:affiliation>Krankenanstalt Rudolfstiftung, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Krankenanstalt Rudolfstiftung, Vienna</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: fifigs1@yahoo.de</mods:affiliation><country wicri:rule="url">Allemagne</country></affiliation><affiliation><mods:affiliation>J. Finsterer, Krankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna, AustriaTel.: +43 1 71165 92085Fax: +43 1 4781711e‐mail:</mods:affiliation></affiliation><affiliation wicri:level="1"><mods:affiliation>E-mail: fifigs1@yahoo.de</mods:affiliation><country wicri:rule="url">Allemagne</country></affiliation></author><author><name sortKey="Loscher, W N" sort="Loscher, W N" uniqKey="Loscher W" first="W. N." last="Löscher">W. N. Löscher</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Wanschitz, J" sort="Wanschitz, J" uniqKey="Wanschitz J" first="J." last="Wanschitz">J. Wanschitz</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Medical University of Innsbruck, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Quasthoff, S" sort="Quasthoff, S" uniqKey="Quasthoff S" first="S." last="Quasthoff">S. Quasthoff</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Graz Medical University, Graz, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Graz Medical University, Graz</wicri:regionArea></affiliation></author><author><name sortKey="Grisold, W" sort="Grisold, W" uniqKey="Grisold W" first="W." last="Grisold">W. Grisold</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Kaiser‐Franz‐Josef Spital, Vienna, Austria</mods:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, Kaiser‐Franz‐Josef Spital, Vienna</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Acta Neurologica Scandinavica</title><title level="j" type="alt">ACTA NEUROLOGICA SCANDINAVICA</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><biblScope unit="vol">134</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="388">388</biblScope><biblScope unit="page" to="402">402</biblScope><biblScope unit="page-count">15</biblScope><date type="published" when="2016-12">2016-12</date></imprint><idno type="ISSN">0001-6314</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background: Some systemic diseases also affect the skeletal muscle to various degrees and with different manifestations. This review aimed at summarizing and discussing recent advances concerning the management of muscle disease in systemic diseases. Method: Literature review by search of MEDLINE, and Current Contents with appropriate search terms. Results: Secondary muscle disease occurs in infectious disease, endocrine disorders, metabolic disorders, immunological disease, vascular diseases, hematological disorders, and malignancies. Muscle manifestations in these categories include pathogen‐caused myositis, muscle infarction, rhabdomyolysis, myasthenia, immune‐mediated myositis, necrotising myopathy, or vasculitis‐associated myopathy. Muscle affection may concern only a single muscle, a group of muscles, or the entire musculature. Severity of muscle affection may be transient or permanent, may be a minor part of or may dominate the clinical picture, or may be mild or severe, requiring invasive measures including artificial ventilation if the respiratory muscles are additionally involved. Diagnostic work‐up is similar to that of primary myopathies by application of non‐invasive and invasive techniques. Treatment of muscle involvement in systemic diseases is based on elimination of the underlying cause and supportive measures. The prognosis is usually fair if the causative disorder is effectively treatable but can be fatal in single cases if the entire musculature including the respiratory muscles is involved, in case of infection, or in case of severe rhabdomyolysis. Conclusion: Secondary muscle manifestations of systemic diseases must be addressed and appropriately managed. Prognosis of secondary muscle disease in systemic diseases is usually fair if the underlying condition is accessible to treatment.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002181 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002181 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:630F32990B32178802FA502E5613B79C73861A80
|texte= Secondary myopathy due to systemic diseases
}}
| This area was generated with Dilib version V0.6.34. |  |